CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Westcott scissors maker Acme United Q3 net sales rise 18% on broad-based growth

By Reuters News


Overview

  • Safety solutions supplier's Q3 net sales rose 18% yr/yr, driven by broad-based growth

  • Q3 diluted EPS rose 74% yr/yr to $0.80

  • Quarter benefited from $4 mln tariff refund, partly offset by facility closure costs


Outlook

  • Company expects My Medic to generate most profitability in Q4 due to seasonality

  • Company says transportation and raw material costs are rising, offset by operational efficiencies

  • Company expects over $1.0 mln in annual savings from DMT plant closure in 2027


Result Drivers

  • BROAD-BASED SALES GROWTH - Co said all business units and international markets contributed to sales growth, with strong back-to-school sales

  • TARIFF REFUND - Co recognized $4 mln tariff refund in Q3, reducing cost of goods sold

  • FACILITY CLOSURE COSTS - Co incurred $1.8 mln in costs related to DMT facility closure and production shift to Asia


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$58.01 mln

$56.39 mln (2 Analysts)

Q3 EPS

$0.80

Q3 Net Income

$3.44 mln

Q3 Basic EPS

$0.88

Q3 Gross Profit

$26.30 mln

Q3 Operating Income

$4.46 mln

Q3 Pretax Profit

$3.86 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Acme United Corp is $63.00, about 0.9% below its October 26 closing price of $63.58

  • The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 26 three months ago


Reuters Recommended Reads

  • Oct 26 - Dorman Products Q3 sales slightly miss estimates on tariff pricing impact

  • Oct 26 - Simpson Manufacturing Q3 sales beat estimates, aided by pricing actions


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.